News
SCM hosts The 5th International Summit on Innovative Drug Discovery
28 October 2023
SCM organised The 5th International Summit on Innovative Drug Discovery on campus on 28 October. The event brought together great minds in the drug discovery field to share insights on policies concerning research and development of innovative drugs as well as paths and practical experience of innovative drug discovery.
Carrying the themes of “New Horizons in Deciphering the Ecological Construction and Investment for New Drug Discovery and Development”, “Strategy and Translational Practice of New Drug Discovery and Development in the New Era” and “Innovator Insights into New Drug Discovery and Development”, the Summit featured 15 talks by officials from the National Medical Products Administration, pharmaceutical entrepreneurs and esteemed scholars from Hong Kong, Macau, Mainland China and Australia. This Summit, held both in-person and online, took on particular significance in light of the recent Government’s focus on Chinese medicine development, infrastructure enhancement, and the strengthening of integrated Chinese-Western medicine services. The timing was also apt, coinciding with the Government's increased funding support for collaborations among governmental entities, industry, academia, and research sectors to commercialise research-and-development outcomes.
In his welcoming address, Professor Alexander Wai, President and Vice-Chancellor of HKBU, emphasised the immense value of Chinese medicine, highlighting its potential to make substantial contributions to public health. He also shared the University's latest achievements in scientific research and clinical studies, underscoring HKBU's dedication to the advancement of health and drug discovery through a scientific and standardised approach.
Speaking at the Ceremony, Professor Jia Wei, Acting Dean of Chinese Medicine, showcased the School’s success stories and remarkable achievements in translating research results into innovative solutions. With a focus on translational research, SCM researchers have been exploring the mechanisms of human diseases and advancing the development of precision medicine and novel treatment options. Looking ahead, SCM will foster collaborations with enterprises and universities to contribute to human well-being.
The 5th International Summit on Innovative Drug Discovery symbolises another significant milestone in our ongoing mission to advance the boundaries of Chinese medicine. With approximately 500 attendees, including researchers, scholars, potential investors, industry experts, Chinese medicine practitioners, and members of the SCM community, the event served as a catalyst for driving Chinese medicine towards a more innovative future.
Professor Jia Wei, Acting Dean of Chinese Medicine, showcased the School’s success stories and remarkable achievements
Representatives from HKBU:
- Professor Lyu Aiping (4th left), Vice President (Research and Development) at HKBU;
- Professor Bian Zhaoxiang (3rd left), Associate Vice-President (Chinese Medicine Development);
- Professor Zhang Ge (5th right), Associate Dean, School of Chinese Medicine (SCM);
- Professor Zhang Hongjie (4th right), Director of CMTR, SCM
Topic: New Horizons in Deciphering the Ecological Construction and Investment for New Drug Discovery and Development
Moderators:
- Professor Jia Wei (5th left), Acting Dean, SCM
- Mr Zhi Zhe (1st left), Vice President, China Resources Enterprise Limited
Speakers:
- Dr. Xu Xiaoqiang (2nd left), Director, Division of Chemical Drugs, Department of Drug Registration (Department of TCMs and Ethno-Medicines Regulation), National Medical Products Administration
- Dr Yu Jiangyong (3rd right), Director, Division of Traditional Chinese Medicine and Ethno-Medicines, Department of Drug Registration (Department of TCM's and Ethno-Medicines Regulation), National Medical Products Administration
- Professor Cheng Long (2nd right), Deputy Secretary-General, Application Assessment and Assurance Committee of the Chinese Medical Information and big data Association
- Mr. Liu Yilun (1st right), Executive Director, Boyu Capital
Topic: Strategy and Translational Practice of New Drug Discovery and Development in the New Era
Moderators:
- Professor Bian Zhaoxiang (1st left), Associate Vice-President (Chinese Medicine Development)
- Professor Feng Yibin (3rd left), Director, School of Chinese Medicine, HKU
- Professor Zhang Ge (2nd right), Associate Dean, SCM
- Dr Lyu Haitao (1st right), Associate Professor, SCM
Speakers:
- Dr Wang Jingsong (5th left), Chairman and Chief Executive Officer, Harbour BioMed
- Professor WANG Xiaoliang (Center), Director, Key Laboratory of Druggability Evaluation and System Translational Medicine, Tianjin Institute of Pharmaceutical Research
- Professor KE Hua Zhu, David (4th left), Chairman and Chief Executive Officer, Angitia Biopharmaceuticals Limited
- Dr Liang Zicai (6th right), Chairman and Chief Executive Officer, Suzhou Ribo Life Science Company Limited
- Dr Li Ming, Chief Executive Officer, ZSHK Laboratories Limited
- Dr Dai Xiaochang (5th right), Executive Director, Chief Strategy Officer of Simaomics Ltd.
- Dr Zhu Guidong (4th right), Chief Executive Officer, Sparx Biopharmaceutical Corporation
Topic: Innovator Insights into New Drug Discovery and Development
Moderators:
- Dr. HUANG Yue (3rd left), Director, Shanghai Biopharma Evolution
- Professor Lin Zhixiu, Director, School of Chinese Medicine, CUHK
Speakers:
- Professor ZHU Yizhun (Center), Associate Vice President, Chair Professor, Macau University of Science and Technology; Member of European Academy of Sciences & Arts; Founder of InnoDrug Lab. (HK) Co., Ltd.
- Dr. GONG Zhaolong, John (4th right), Chairman and Chief Executive Officer, 3D Medicines, Inc.
- Professor ZHENG Minghao, Medical School, The University of Western Australia
- Dr. HE Yixin (4th left), Chairman and Chief Executive Officer, Aptacure Therapeutics Limited